Skip to main content
    K

    Kyverna Therapeutics, Inc. Common Stock (KYTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.76
    -0.29 (-5.74%)

    Market Cap: $319.27M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Kyverna Therapeutics, Inc. Common Stock (KYTX) Financials: Revenue, Profit and Cash Flow

    Updated Nov 12, 2026. Financial statements from company filings, amounts in US dollars.

    Kyverna Therapeutics, Inc. Common Stock reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$161.31M, operating cash flow was -$153.71M and free cash flow was -$154.84M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$41.94M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $169.83M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0-100.0%N/AN/AN/A
    Dec 2022$7.03M+24.2%100.0%-418.3%-411.3%
    Dec 2021$5.66MN/A100.0%-465.8%-465.9%
    Annual, fiscal years ended Dec 2021 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
    Revenue$0$0$0$7.03M$5.66M
    Cost of revenue$0$0$0$1.05M$586.00K
    Gross profit$0$0$0$7.03M$5.66M
    Research and development$133.72M$112.47M$49.92M$28.40M$25.85M
    Operating income-$169.83M-$142.60M-$62.41M-$29.38M-$26.35M
    Net income-$161.31M-$127.48M-$60.37M-$28.89M-$26.35M
    EBITDAN/AN/A-$61.87M-$27.78M-$25.76M
    Fiscal years ended Dec 2021 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$0$2.02M$0$0$0$0
    Gross profit$0$0$0-$368.00K$0$0$0-$563.00K$0$0$0-$17.16M
    Operating income-$42.90M-$39.56M-$41.37M-$39.28M-$38.73M-$44.41M-$47.41M-$41.04M-$38.77M-$33.44M-$29.36M-$21.38M
    Net income-$41.94M-$38.32M-$39.73M-$37.80M-$36.79M-$42.08M-$44.63M-$37.49M-$34.49M-$28.80M-$26.69M-$20.67M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $28.71M by $95.38M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
    Total assets$293.83M$304.64M$75.19M$66.92M$85.49M
    Current assets$282.95M$290.60M$60.66M$53.25M$77.09M
    Cash and equivalents$124.09M$96.62M$34.65M$37.73M$76.07M
    Total liabilities$61.55M$38.06M$26.02M$20.25M$131.74M
    Short-term debt$3.97M$3.94M$2.92M$2.28M$814.00K
    Long-term debt$24.74M$0N/AN/AN/A
    Shareholder equity$232.28M$266.59M-$131.40M$46.68M-$46.25M
    Fiscal years ended Dec 2021 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$189.44M$219.82M$257.02M$293.83M$187.16M$226.51M$260.65M$304.64M$339.20M$363.12M$389.98M$75.19M
    Total liabilities$56.28M$54.27M$61.44M$61.55M$35.21M$42.13M$36.65M$38.06M$36.49M$29.61M$28.99M$26.02M
    Cash and equivalents$31.82M$31.81M$32.19M$124.09M$34.16M$53.44M$56.87M$96.62M$104.66M$131.62M$224.29M$34.65M
    Shareholder equity$133.15M$165.55M$195.58M$232.28M$151.95M$184.38M$224.01M$266.59M$302.71M$333.51M$360.99M$49.18M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
    Operating cash flow-$153.71M-$114.25M-$52.41M-$36.11M-$22.16M
    Capital expenditures$1.13M$2.21M$621.00K$768.00K$1.29M
    Free cash flow-$154.84M-$116.45M-$53.03M-$36.88M-$23.44M
    Share repurchases$475.00K$3.36M$1.65MN/AN/A
    Investing cash flow$40.02M-$160.90M-$8.79M-$14.10M-$1.29M
    Financing cash flow$141.17M$337.11M$58.12M$11.88M$72.52M
    Fiscal years ended Dec 2021 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$35.37M-$40.31M-$41.60M-$33.53M-$43.32M-$31.95M-$44.91M-$37.06M-$27.49M-$24.18M-$25.52M-$18.56M
    Capital expenditures$525.00K$548.00K$0$537.00K$392.00K$204.00K$0$532.00K$102.00K$1.03M$543.00K$334.00K
    Free cash flow-$35.89M-$40.85M-$41.60M-$34.06M-$43.71M-$32.15M-$44.91M-$37.59M-$27.59M-$25.20M-$26.07M-$18.90M
    Last 12 quarters

    Frequently Asked Questions About KYTX

    What is Kyverna Therapeutics, Inc. Common Stock's annual revenue?

    Kyverna Therapeutics, Inc. Common Stock reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Kyverna Therapeutics, Inc. Common Stock profitable?

    No. Kyverna Therapeutics, Inc. Common Stock reported net income of -$161.31M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does KYTX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$153.71M minus capital expenditures of $1.13M produced free cash flow of -$154.84M.

    How much debt does Kyverna Therapeutics, Inc. Common Stock have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $24.74M, short-term debt of $3.97M and cash and equivalents of $124.09M.